Core Viewpoint - The article highlights the successful launch of the AI-driven HCAb model by Heptares Therapeutics, which is expected to revolutionize the development of next-generation therapeutic antibodies and enhance drug discovery processes [1] Company Developments - Heptares Therapeutics' stock rose over 4%, currently trading at 13.49 HKD with a transaction volume of 52.54 million HKD [1] - The company hosted the "Zhi Yao He Po Hui Chuang Xing Chen" Global R&D Day in Shanghai on October 28, where it unveiled its first fully human AI HCAb model [1] Technology and Innovation - The AI HCAb model is based on Heptares' proprietary Harbour Mice platform data and integrates a fine-tuned large language model (LLM) for sequence generation, along with high-precision AI classification and drugability prediction models [1] - This platform establishes a closed-loop process that combines AI design, intelligent screening, and wet lab validation, differentiating it from traditional screening methods [1] Market Implications - The AI HCAb model is anticipated to accelerate the application of fully human HCAb in next-generation therapeutic areas, including multispecific antibodies, XDC, in vivo CAR-T, and inhaled or oral macromolecular drugs [1] - Heptares aims to reshape the landscape of biopharmaceutical development by leveraging AI capabilities and HCAb technology to address unmet clinical needs through data-driven predictive processes [1]
和铂医药-B涨超4% 发布首个全人源HCAb生成模型 加速新一代疗法落地